Multiple Myeloma Market Segmentation:
- By Drug Class
- Immunomodulatory drugs (IMiDs)
- Proteasome inhibitors
- Monoclonal antibodies
- Histone deacetylase inhibitors
- Immunotherapies
- By Route of Administration
- Oral
- Injectable
- Intravenous
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Line of Treatment
- Frontline
- Second-line
- Third-line and beyond
- By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
- North America
Frequently Asked Questions
US$ 16.6 billion in 2023
Rising incidence globally, Launch of novel therapies, Advances in combination treatment, Improved diagnosis, Rising pharmaceutical R&D spending, Growth opportunities in emerging markets
Low diagnosis rates, High treatment costs, Adverse effects of therapeutics, Patent expirations of top drugs
The immunomodulatory drugs (IMiDs) segment accounts for the largest share of the multiple myeloma market. IMiDs like Revlimid and Pomalyst are widely used for MM treatment.
Takeda, Janssen, Bristol Myers Squibb, Amgen, Novartis, AbbVie, GlaxoSmithKline, Roche, Merck, Johnson & Johnson
CAGR of 5.8% Market Size - US$ 26.1 billion in 2031
Aging population, Rising incidence rates, New drug launches, Advances in therapies, Improved diagnosis, Favorable reimbursement